Abstract
There is a lack of COVID-19 adjusted case fatality risk (aCFR) estimates and information on states with high aCFR. State-specific aCFRs were estimated, using 13-day lag for fatality. To estimate country-level aCFR, state estimates were meta-analysed. Multiple correspondence analyses (MCA), followed by univariable logistic regression, were conducted to understand the association between aCFR and geodemographic, health and social indicators. Based on health indicators, states likely to report a higher aCFR were identified. Using random- and fixed-effects models, the aCFRs in India were 1.42 (95% CI 1.19 – 1.70) and 2.97 (95% CI 2.94 – 3.00), respectively. The aCFR was grouped with the incidence of diabetes, hypertension, cardiovascular diseases and acute respiratory infections in the first and second dimensions of MCA. The current study demonstrated the value of using meta-analysis to estimate aCFR. To decrease COVID-19 associated fatalities, states estimated to have a high aCFR must take steps to reduce co-morbidities.
Article Summary Line Meta-analysis and the COVID-19 adjusted case fatality risks (aCFRs) in India are reported and states likely to report a higher aCFR have been identified.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Non-funded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The corresponding author had full access to all data in the study and will be supplied on request by the corresponding author.